Axillary Lymph Node Staging in Breast Cancer by 2-Fluoro-2-deoxy-d-glucose–Positron Emission Tomography: Clinical Evaluation and Alternative Management

• Published in: JNCI : Journal of the National Cancer Institute Vol. 93; no. 8; pp. 630 - 635
• Main Authors: Greco, Marco, Crippa, Flavio, Agresti, Roberto, Seregni, Ettore, Gerali, Alberto, Giovanazzi, Riccardo, Micheli, Andrea, Asero, Salvatore, Ferraris, Cristina, Gennaro, Massimiliano, Bombardieri, Emilio, Cascinelli, Natale
• Format: Journal Article
• Language: English
• Published: Cary, NC Oxford University Press 18.04.2001; Oxford Publishing Limited (England)
• Subjects: Adult; Aged; Aged, 80 and over; Axilla; Biological and medical sciences; Breast Neoplasms - diagnostic imaging; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Breast Neoplasms - surgery; Endocrine glands. Genital system. Mammary gland; Female; Fluorodeoxyglucose F18 - pharmacokinetics; Humans; Investigative techniques, diagnostic techniques (general aspects); Lymph Node Excision; Lymph Nodes - diagnostic imaging; Lymph Nodes - metabolism; Lymph Nodes - pathology; Lymph Nodes - surgery; Lymphatic Metastasis; Medical sciences; Middle Aged; Neoplasm Staging; Prospective Studies; Radionuclide investigations; Radiopharmaceuticals - pharmacokinetics; Tomography, Emission-Computed; Radionuclide study; Human; Mammary gland diseases; Clinical stage; Fluorine Isotopes; Lymph node; Non invasive method; Mammary gland; Radioisotope; Malignant tumor; Positron; Emission tomography
• ISSN: 0027-8874; 1460-2105
• DOI: 10.1093/jnci/93.8.630

Background: Surgical removal of axillary lymph node and histologic examination for metastases are used to determine whether adjuvant treatment is necessary for patients with breast cancer. Axillary lymph node dissection (ALND) is a costly procedure associated with various side effects, and 80% or more of patients with tumors of 20 mm or less are lymph node negative and might avoid ALND. In this study, we evaluated whether an alternative, noninvasive method—i.e., positron emission tomography (PET) with 2-[18F]fluoro-2-deoxy-d-glucose (FDG)— could be used to determine axillary lymph node status in patients with breast cancer. Methods: One hundred sixty-seven consecutive patients with breast cancers of 50 mm or less (range = 5–50 mm; mean = 21 mm) scheduled for complete ALND were studied preoperatively with FDG–PET, and then PET and pathology results from ALND were compared. All statistical tests were two-sided. Results: The overall sensitivity, specificity, and accuracy of lymph node staging with PET were 94.4% (PET detected 68 of 72 patients with axillary involvement; 95% confidence interval [CI] = 86.0% to 98.2%), 86.3% (82 of 95 patients without axillary involvement; 95% CI = 77.8% to 91.9%), and 89.8% (150 of 167 patients with breast cancer; 95% CI = 84.2% to 93.6%), respectively. Positive- and negative-predictive values were 84.0% (68 patients with histologically positive lymph nodes of 81 patients with positive FDG–PET scan; 95% CI = 74.2% to 90.5%) and 95.3% (82 patients with histologically negative lymph nodes of 86 patients with negative FDG–PET scan; 95% CI = 88.2% to 98.5%), respectively. When PET results for axillary metastasis were analyzed by tumor size, the diagnostic accuracy was similar for all groups (86.0%–94.2%), with higher sensitivity for tumors of 21–50 mm (98.0%) and higher specificity for tumors of 10 mm or less (87.8%), and the range was 93.5%–97.3% for negative-predictive values and 54.5%–94.1% for positive-predictive values. Among the 72 patients with axillary involvement, PET detected three or fewer metastatic lymph nodes in 27 (37.5%) patients, about 80% of whom had no clinically palpable axillary lymph nodes. Conclusions: Noninvasive FDG–PET appears to be an accurate technique to predict axillary status in patients with breast cancer and thus to identify patients who might avoid ALND. These results should be confirmed in large multicenter studies.